SEC Form 4 · accession 0001628280-26-041281
Acumen Pharmaceuticals, Inc. · ABOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nathan B Fountain
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576885
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 3, 2026 | A | 35,500 | $0.00 | A | 54,550 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.29 | Jun 3, 2026 | A | 53,250 | A | — | Jun 3, 2036 | Common Stock | 53,250 | 53,250 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- F2The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.